These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20691045)

  • 21. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study.
    Walker AS; Doerholt K; Sharland M; Gibb DM;
    AIDS; 2004 Sep; 18(14):1915-24. PubMed ID: 15353977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Younger age at HAART initiation is associated with more rapid growth reconstitution.
    McGrath CJ; Chung MH; Richardson BA; Benki-Nugent S; Warui D; John-Stewart GC
    AIDS; 2011 Jan; 25(3):345-55. PubMed ID: 21102302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children.
    Wamalwa DC; Farquhar C; Obimbo EM; Selig S; Mbori-Ngacha DA; Richardson BA; Overbaugh J; Emery S; Wariua G; Gichuhi C; Bosire R; John-Stewart G
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):311-7. PubMed ID: 17356470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of HAART on survival, weight gain and resting energy expenditure in HIV-1-infected children in India.
    Banerjee T; Pensi T; Banerjee D; Grover G
    Ann Trop Paediatr; 2010; 30(1):27-37. PubMed ID: 20196931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in factors associated with initial growth, CD4, and viral load responses to ART in HIV-infected children in Kampala, Uganda, and the United Kingdom/Ireland.
    Kekitiinwa A; Lee KJ; Walker AS; Maganda A; Doerholt K; Kitaka SB; Asiimwe A; Judd A; Musoke P; Gibb DM; ;
    J Acquir Immune Defic Syndr; 2008 Dec; 49(4):384-92. PubMed ID: 18931630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of tuberculosis-HIV co-treatment on clinical and growth outcomes among hospitalized children newly initiating antiretroviral therapy.
    Cherkos AS; Cranmer LM; Njuguna I; LaCourse SM; Mugo C; Moraa H; Maleche-Obimbo E; Enquobahrie DA; Richardson BA; Wamalwa D; John-Stewart G
    AIDS; 2024 Mar; 38(4):579-588. PubMed ID: 38016160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site Canadian cohort.
    Cescon AM; Cooper C; Chan K; Palmer AK; Klein MB; Machouf N; Loutfy MR; Raboud J; Rachlis A; Ding E; Lima VD; Montaner JS; Rourke SB; Smieja M; Tsoukas C; Hogg RS;
    HIV Med; 2011 Jul; 12(6):352-60. PubMed ID: 21059167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa.
    Huet C; Ouedraogo A; Konaté I; Traore I; Rouet F; Kaboré A; Sanon A; Mayaud P; Van de Perre P; Nagot N
    BMC Public Health; 2011 Sep; 11():700. PubMed ID: 21917177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiretroviral treatment for children.
    Eley B; Davies MA; Apolles P; Cowburn C; Buys H; Zampoli M; Finlayson H; King S; Nuttall J
    S Afr Med J; 2006 Sep; 96(9 Pt 2):988-93. PubMed ID: 17077930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
    HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth response to antiretroviral treatment in HIV-infected children: a cohort study from Lilongwe, Malawi.
    Weigel R; Phiri S; Chiputula F; Gumulira J; Brinkhof M; Gsponer T; Tweya H; Egger M; Keiser O
    Trop Med Int Health; 2010 Aug; 15(8):934-44. PubMed ID: 20561308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late starters.
    Waters L; Fisher M; Anderson J; Wood C; Delpech V; Hill T; Walsh J; Orkin C; Bansi L; Gompels M; Phillips A; Johnson M; Gilson R; Easterbrook P; Leen C; Porter K; Gazzard B; Sabin C;
    HIV Med; 2011 May; 12(5):289-98. PubMed ID: 21054749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy.
    Saitoh A; Singh KK; Sandall S; Powell CA; Fenton T; Fletcher CV; Hsia K; Spector SA
    J Allergy Clin Immunol; 2006 Apr; 117(4):909-15. PubMed ID: 16630951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of an antiretroviral access program for HIV-1-infected individuals in resource-limited settings: clinical results from 4 African countries.
    Sow PS; Otieno LF; Bissagnene E; Kityo C; Bennink R; Clevenbergh P; Wit FW; Waalberg E; Rinke de Wit TF; Lange JM;
    J Acquir Immune Defic Syndr; 2007 Mar; 44(3):262-7. PubMed ID: 17146376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
    Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
    Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact on weight and height with the use of HAART in HIV-infected children.
    Guillén S; Ramos JT; Resino R; Bellón JM; Muñoz MA
    Pediatr Infect Dis J; 2007 Apr; 26(4):334-8. PubMed ID: 17414398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Nachman SA; Lindsey JC; Moye J; Stanley KE; Johnson GM; Krogstad PA; Wiznia AA;
    Pediatr Infect Dis J; 2005 Apr; 24(4):352-7. PubMed ID: 15818296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-Term Immunological and Virological Outcomes in Children Receiving Highly Active Antiretroviral Therapy at Hawassa University College of Medicine and Health Sciences, Southern Ethiopia.
    Fenta DA; Wube TB; Nuru MM
    J Immunol Res; 2021; 2021():2498025. PubMed ID: 33928167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.